Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | ICMT | O60725 | 1/20 | 0.48 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15941034 | 1.00 | SGMS2 (0.58) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL15941211 | 1.00 | SGMS2 (0.58) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL7956086 | 0.90 | SGMS2 (0.55) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL15947711 | 0.90 | SGMS2 (0.55) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL7723403 | 0.90 | SGMS2 (0.55) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL7723401 | 0.90 | SGMS2 (0.55) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL7956090 | 0.90 | SGMS2 (0.55) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL15941245 | 0.90 | SGMS2 (0.55) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL17389356 | 0.87 | SGMS2 (0.55) | SGMS2NPC1GAAMEN1KMT2A | |
| SCHEMBL15947736 | 0.87 | SGMS2 (0.55) | SGMS2NPC1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1315962-A | Novel method for synthesizing Exochelins | KEYSTONE BIOMEDICAL INC (US) | 2001-10-03 | — | — | CN | claimed |
| EP-1105416-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | Keystone Biomedical, Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| US-6063919-A | ESTERIFICATION OF O-DEPROTECTED DIBENZYL EXOCHELIC ACID WITH BENZYL EPI-COBACTIN, HYDROGENOLYTICALLY REMOVING THE THREE BENZYL GROUPS TO FORM EXOCHELIN 786SM(R) | KEYSTONE BIOMEDICAL, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-2000009547-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | KEYSTONE BIOMEDICAL, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| US-20160002269-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-01-07 | — | — | US | disclosed |
| EP-2953899-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | Yeda Research and Development Co., Ltd. (IL) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014122664-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014122664-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-08-14 | — | — | WO | disclosed |
| EP-1105416-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | Keystone Biomedical, Inc. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000009547-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | KEYSTONE BIOMEDICAL, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002269-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | VAC14, LPXN, SLC39A7 | SGMS2 3429/4885NPC1 3667/4885GAA 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.